Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.64 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.64 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.64 |
| ▸ | LCK | P06239 | 1/20 | 0.57 |
| ▸ | CSF1R | P07333 | 1/20 | 0.57 |
| ▸ | KDR | P35968 | 1/20 | 0.57 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.55 |
| ▸ | RAF1 | P04049 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26622758 | 0.99 | MAPK14 (0.68) | MAPK14CYP2C9HSPB1MAPK11LCK | |
| SCHEMBL26622703 | 0.99 | MAPK14 (0.68) | MAPK14CYP2C9HSPB1MAPK11LCK | |
| SCHEMBL26622702 | 0.97 | MAPK14 (0.70) | MAPK14CYP2C9HSPB1MAPK11LCK | |
| SCHEMBL26622796 | 0.95 | MAPK14 (0.73) | MAPK14CYP2C9HSPB1MAPK11LCK | |
| SCHEMBL5631456 | 0.90 | MAPK14 (0.81) | MAPK14CYP2C9HSPB1MAPK11LCK | |
| SCHEMBL26622710 | 0.89 | MAPK14 (0.68) | MAPK14CYP2C9HSPB1MAPK11LCK | |
| SCHEMBL5630096 | 0.88 | MAPK14 (0.87) | MAPK14CYP2C9HSPB1MAPK11LCK | |
| SCHEMBL26716816 | 0.87 | MAPK14 (0.65) | MAPK14CYP2C9HSPB1MAPK11LCK | |
| SCHEMBL30678666 | 0.86 | MAPK14 (0.64) | MAPK14CYP2C9HSPB1MAPK11LCK | |
| SCHEMBL30678671 | 0.86 | MAPK14 (0.64) | MAPK14CYP2C9HSPB1MAPK11LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109839-A1 | NOVEL COMPOUND EXHIBITING ANTI-INFLAMMATORY ACTIVITY AS P38 MAP KINASE INHIBITOR | PRAZERTHERAPEUTICS INC. (KR) | 2024-04-04 | — | — | US | claimed |
| EP-4273120-A1 | NOVEL COMPOUND EXHIBITING ANTI-INFLAMMATORY ACTIVITY AS P38 MAP KINASE INHIBITOR | Prazertherapeutics Inc. (KR) | 2023-11-08 | — | — | EP | claimed |
| US-20240109839-A1 | NOVEL COMPOUND EXHIBITING ANTI-INFLAMMATORY ACTIVITY AS P38 MAP KINASE INHIBITOR | PRAZERTHERAPEUTICS INC. (KR) | 2024-04-04 | — | — | US | disclosed |
| CN-117136177-A | Novel compounds exhibiting anti-inflammatory activity as P38MAP kinase inhibitors | 普瑞泽治疗公司 | 2023-11-28 | — | — | CN | disclosed |
| EP-4273120-A1 | NOVEL COMPOUND EXHIBITING ANTI-INFLAMMATORY ACTIVITY AS P38 MAP KINASE INHIBITOR | Prazertherapeutics Inc. (KR) | 2023-11-08 | — | — | EP | disclosed |
| WO-2022164041-A1 | NOVEL COMPOUND EXHIBITING ANTI-INFLAMMATORY ACTIVITY AS P38 MAP KINASE INHIBITOR | (주)프레이저테라퓨틱스 | 2022-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109839-A1 | NOVEL COMPOUND EXHIBITING ANTI-INFLAMMATORY ACTIVITY AS P38 MAP KINASE INHIBITOR | MAPK1, MAPKAPK2, MAPKAPK5 | MAPK14 12/4885CYP2C9 4016/4885HSPB1 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.